Heterozygous Familial Hypercholesterolemia study: VERVE-102
Official title A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease
ClinicalTrials.gov ID: NCT06164730
What this study is testing
What is VERVE-102?
VERVE-102 is an investigational medicine being studied to help lower cholesterol in people with specific heart disease risks. It is designed to use a technology called base-editing to stop the liver from making a protein called PCSK9, which may help lower bad cholesterol levels.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study wants to see if VERVE‑102 is safe and how it changes cholesterol levels in patients with high LDL‑C or early coronary artery disease.
- Who it's for
- It is looking for adults who have heterozygous familial hypercholesterolemia or premature coronary heart disease and need more LDL‑C lowering.
- What's involved
- Participants will receive a single dose of VERVE‑102 and will have blood tests and safety checks before and after the injection.
- Time commitment
- The study lasts a few weeks, with a few clinic visits for blood draws and safety monitoring.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 70
You may be able to join if
- Diagnosis of HeFH or premature CAD
You likely can't join if
- Homozygous familial hypercholesterolemia
- Active or history of chronic liver disease
- Current treatment with PCSK9 inhibitor or prior treatment within specified timeframe
- Clinically significant or abnormal laboratory values as defined by the protocol
The study team makes the final eligibility decision.
Where it is enrolling
- Dothan, Alabama, United States
- Pomona, California, United States
- Boca Raton, Florida, United States
- Jacksonville, Florida, United States
- Winter Park, Florida, United States
- Indianapolis, Indiana, United States
- High Point, North Carolina, United States
- Philadelphia, Pennsylvania, United States
- DeSoto, Texas, United States
- Renton, Washington, United States
- Adelaide, Australia
- Melbourne, Australia
- Sydney, Australia
- Chicoutimi, Canada
- Hamilton, Canada
- Montreal, Canada
- Québec, Canada
- Toronto, Canada
- Vancouver, Canada
- Rehovot, Israel
+ 7 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 70 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Dothan, Alabama, United States; Pomona, California, United States; Boca Raton, Florida, United States; Jacksonville, Florida, United States; Winter Park, Florida, United States; Indianapolis, Indiana, United States and 21 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.